TY - JOUR
T1 - Oncotype dx test receipt among latina/hispanic women with early invasive breast cancer in new jersey
T2 - A registry-based study
AU - Acuna, Nicholas
AU - Plascak, Jesse J.
AU - Tsui, Jennifer
AU - Stroup, Antoinette M.
AU - Llanos, Adana A.M.
N1 - Funding Information:
This work was partially supported by Cancer Center Support Grant P30CA072720 (New Investigator Award to AAML), Exito! Latino Cancer Research Leadership Training (awarded to NA) through the Institute for Health Promotion Research at UT Health San Antonio (2R25CA134301-06), and by the New Jersey State Cancer Registry (NJSCR). Cancer Epidemiology Services, including the New Jersey State Cancer Registry, receives financial support from the: Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, National Institutes of Health, under Contract HHSN 261201300021I and Control No. N01-PC-2013-00021; National Program of Cancer Registries, Centers for Disease Control and Prevention, under cooperative agreement 5U58/DP003931; and the State of New Jersey and Rutgers Cancer Institute of New Jersey.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/5/2
Y1 - 2021/5/2
N2 - Oncotype DX® (ODX) is a valid test of breast cancer (BC) recurrence risk and chemotherapy benefit. The purpose of this study was to examine prevalence of and factors associated with receipt of ODX testing among eligible Latinas/Hispanics diagnosed with BC. Sociodemographic and tumor data of BC cases diagnosed between 2008 and 2017 among Latina/Hispanic women (n = 5777) were from the New Jersey State Cancer Registry (NJSCR). Eligibility for ODX testing were based on National Comprehensive Cancer Network guidelines. Multivariable logistic regression models of ODX receipt among eligible women were used to estimate adjusted odds ratios (AOR) and 95% con-fidence intervals (CI) by demographic and clinicopathologic factors. One-third of Latinas/Hispanics diagnosed with BC were eligible for ODX testing. Among the eligible, 60.9% received ODX testing. Older age (AOR 0.08, 95% CI: 0.04, 0.14), low area-level SES (AOR 0.58, 95% CI: 0.42, 0.52), and being uninsured (AOR 0.58, 95% CI: 0.39, 0.86) were associated with lower odds of ODX testing. While there was relatively high ODX testing among eligible Latina/Hispanic women with BC in New Jersey, our findings suggest that age, insurance status, and area-level SES contribute to unequal access to genetic testing in this group, which might impact BC outcomes.
AB - Oncotype DX® (ODX) is a valid test of breast cancer (BC) recurrence risk and chemotherapy benefit. The purpose of this study was to examine prevalence of and factors associated with receipt of ODX testing among eligible Latinas/Hispanics diagnosed with BC. Sociodemographic and tumor data of BC cases diagnosed between 2008 and 2017 among Latina/Hispanic women (n = 5777) were from the New Jersey State Cancer Registry (NJSCR). Eligibility for ODX testing were based on National Comprehensive Cancer Network guidelines. Multivariable logistic regression models of ODX receipt among eligible women were used to estimate adjusted odds ratios (AOR) and 95% con-fidence intervals (CI) by demographic and clinicopathologic factors. One-third of Latinas/Hispanics diagnosed with BC were eligible for ODX testing. Among the eligible, 60.9% received ODX testing. Older age (AOR 0.08, 95% CI: 0.04, 0.14), low area-level SES (AOR 0.58, 95% CI: 0.42, 0.52), and being uninsured (AOR 0.58, 95% CI: 0.39, 0.86) were associated with lower odds of ODX testing. While there was relatively high ODX testing among eligible Latina/Hispanic women with BC in New Jersey, our findings suggest that age, insurance status, and area-level SES contribute to unequal access to genetic testing in this group, which might impact BC outcomes.
KW - 21-gene assay
KW - Breast cancer
KW - Latina/Hispanic women
KW - Oncotype DX®
KW - Recurrence risk scores
UR - http://www.scopus.com/inward/record.url?scp=85105737419&partnerID=8YFLogxK
U2 - 10.3390/ijerph18105116
DO - 10.3390/ijerph18105116
M3 - Article
C2 - 34065945
AN - SCOPUS:85105737419
SN - 1661-7827
VL - 18
JO - International journal of environmental research and public health
JF - International journal of environmental research and public health
IS - 10
M1 - 5116
ER -